Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Ngantcha, M, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies. Expert Opinion On Drug Safety. 2024; 23(10)DOI:10.1080/14740338.2024.2399092. PMID:39234767. IF:3.100(Q2/4D).

Doblas, JJG, García-Moll, X, Freire, RB, Juanatey, CG, Morillas, M, Muñoz, AV, Escobar, C. Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting. Future Cardiology. 2024; 20(13)DOI:10.1080/14796678.2024.2343550. PMID:39439239. IF:(Q/D).

Saposnik, G, Monreal, E, Medrano, N, García-Domínguez, JM, Querol, L, Meca-Lallana, JE, Landete, L, Salas, E, Meca-Lallana, V, García-Arcelay, E, Agüera-Morales, E, Martínez-Yélamos, S, Gómez-Ballesteros, R, Maurino, J, Villar, LM, Caminero, AB. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?. Multiple Sclerosis and Related Disorders. 2024; 90DOI:10.1016/j.msard.2024.105838. PMID:39216454. IF:2.900(Q2/4D).

Allen, JA, Lin, J, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Chang, T, Lipowska, M, Lowe, M, Lauria, G, Querol, L, Simu, MA, Suresh, N, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA, van Doorn, PA. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. LANCET NEUROLOGY. 2024; 23(10)DOI:10.1016/S1474-4422(24)00309-0. PMID:39304241. IF:45.500(Q1/1D).

Bolano-Díaz, C, Verdú-Díaz, J, Díaz-Manera, J. MRI for the diagnosis of limb girdle muscular dystrophies. CURRENT OPINION IN NEUROLOGY. 2024; 37(5)DOI:10.1097/WCO.0000000000001305. PMID:39132784. IF:4.400(Q1/2D).

Gawinska, KA, García, MF, Osorio, AN, Paradas, C, Sotoca, J, Povedano, M, Moreno, A, Henao, M, Gil, C, Rojas, R, Caravaca, MG, Grimalt, M, Torron, RF, Jericó, I, Campos, OG, de Laguna, LTB, Hervás, D, Tizzano, E, Costa, JV. Natural history of spinal muscular atrophy patients with 3 and 4 copies of SMN2 gene - data from the national Spanish registry (CUIDAME). NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.461. PMID:. IF:2.800(Q2/5D).

Collins, C, Gokul-Nath, R, Katsikis, P, Fernández-Simón, E, Villalobos, E, Monceau, A, Reza, M, Mehra, P, Laidler, Z, Clark, J, Rojas-García, R, Tasca, G, Marini-Bettolo, C, Diaz-Manera, J. SnRNAseq analysis of muscle samples of patients with SMA reveals novel pathogenic pathways and open avenues for new therapeutic strategies. NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.611. PMID:. IF:2.800(Q2/5D).

Hilsden, H, James, M, Dressman, HG, Rufibach, L, Day, J, Mendell, J, Torron, RF, Harms, M, Pestronk, A, Vissing, J, Desai, U, Yoshimura, M, Shin, J, Mozaffar, T, Stojkovic, T, Pegoraro, E, Rivas, JB, Olive, M, Paradas, C, Straub, V. The International Clinical Outcome Study for Dysferlinopathy II: validation of motor outcome measures in a new patient cohort. NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.276. PMID:. IF:2.800(Q2/5D).

Marín, RM, Leiva, DR, Osorio, AN, Muelas, N, Domínguez, C, Marcos, IR, Paradas, C, Olivé, M, Matas, A, Caravaca, MG, Romero, MB, Mendoza, M, de León, J, Gutiérrez, A, Rabasa, M, Segovia, S, Manera, JD. Spanish Pompe Registry: overview based on the 130 patients included. NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.732. PMID:. IF:2.800(Q2/5D).

Segarra-Casas, A, Domínguez-González, C, Natera-De-Benito, D, Ortez, C, Nascimiento, A, Hernández-Laín, A, Kapetanovic, S, Rodríguez, M, González-Mera, L, Nedkova, V, Fernández-Torrón, R, López-de Munain, A, Jimenez-Mallebrera, C, Rodríguez-Santiago, B, Gallardo, E, Olivé, M, Gallano, P, González-Quereda, L. RNA sequencing as a diagnostic tool in a cohort of 54 undiagnosed patients with neuromuscular diseases. NEUROMUSCULAR DISORDERS. 2024; 43DOI:. PMID:. IF:2.800(Q2/5D).

Herrero-Lorenzo, M, Pérez-Pérez, J, Escaramís, G, Martínez-Horta, S, Pérez-González, R, Rivas-Asensio, E, Kulisevsky, J, Gámez-Valero, A, Martí, E. Small RNAs in plasma extracellular vesicles define biomarkers of premanifest changes in Huntington's disease. Journal of Extracellular Vesicles. 2024; 13(10)DOI:10.1002/jev2.12522. PMID:39377487. IF:14.500(Q1/1D).

Santisteban, V, Muñoz-Garcia, N, López-Yerena, A, Puntes, M, Badimon, L, Padro, T. Efficacy of Food Industry By-Product ß-Glucan/Chitin-Chitosan on Lipid Profile of Overweight and Obese Individuals: Sustainability and Nutraceuticals. Nutrients. 2024; 16(19)DOI:10.3390/nu16193420. PMID:39408385. IF:5.000(Q1/2D).

Perelló, PM, Hurtado, JC, Rodríguez, MP, Arbós, RMA. Understanding sex-based differences by adverse events. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2024; 135DOI:. PMID:. IF:3.300(Q2/4D).

Espinoza, CED, Carrillo, DLR, Simonetti, AF, Pereyra, FG, De Andrade, FC, Schlegel, PA, Ysasis, YM, Reus, FSA, Pestana, MJC, Arbos, RMA. Effectiveness, adequacy and costs of the antibiotic treatment in adult patients with non-cystic fibrosis bronchiectasis and primary infection by Pseudomonas aeruginosa. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2024; 135DOI:. PMID:. IF:3.300(Q2/4D).

Pestana, MJC, Hosey, KCA, Arbós, RA. Drug-induced liver injury (DILI) due anakinra in adult-onset Still's disease (AOSD): Two case reports and review. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2024; 135DOI:. PMID:. IF:3.300(Q2/4D).

Soler, J, Otero, D, Elices, M, Farres, CC, Vera, J, Pascual, JC. Exploring direct experience as a core element behind mindfulness-based cognitive therapy. EUROPEAN JOURNAL OF PSYCHIATRY. 2024; 38(4)DOI:10.1016/j.ejpsy.2024.100268. PMID:. IF:1.500(Q3/7D).

Casellas-Pujol, E, Soler, J, Schmidt, C, Soria-Madrid, A, Elices, M, Pascual, JC. Contextual-compassion training for borderline personality disorder with long lasting symptoms: A randomized clinical trial. Journal of Contextual Behavioral Science. 2024; 34DOI:10.1016/j.jcbs.2024.100846. PMID:. IF:3.000(Q1/3D).

Bonifacio, DM, Rodríguez, MP, Perelló, PM, Hurtado, JC, Albet, JT, Tutusaus, XR, Arbós, RMA. A pilot, randomized, three-arm, dose-finding, placebo-controlled, parallel study to evaluate the use of nabiximols (THC plus CBD, Sativex^®) for cannabis detoxification treatment versus treatment as usual. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2024; 135DOI:. PMID:. IF:3.300(Q2/4D).

Cano, A, Capdevila, M, Puerta, R, Arranz, J, Montrreal, L, de Rojas, I, García-González, P, Olivé, C, García-Gutiérrez, F, Sotolongo-Grau, O, Orellana, A, Aguilera, N, Ramis, M, Rosende-Roca, M, Lleó, A, Fortea, J, Tartari, JP, Lafuente, A, Vargas, L, Pérez-Cordón, A, Muñoz, N, Sanabria, A, Alegret, M, Morató, X, Tárraga, L, Fernández, V, Marquié, M, Valero, S, Alcolea, D, Boada, M, Ruiz, A. Clinical value of plasma pTau181 to predict Alzheimer's ' s disease pathology in a large real-world cohort of a memory clinic. EBioMedicine. 2024; 108DOI:10.1016/j.ebiom.2024.105345. PMID:39299003. IF:10.800(Q1/1D).

Pascoal, TA, Aguzzoli, CS, Lussier, FZ, Crivelli, L, Suemoto, CK, Fortea, J, Rosa-Neto, P, Zimmer, ER, Ferreira, PCL, Bellaver, B. Insights into the use of biomarkers in clinical trials in Alzheimer's ' s disease. EBioMedicine. 2024; 108DOI:10.1016/j.ebiom.2024.105322. PMID:39366844. IF:10.800(Q1/1D).